| Trial ID: | L2175 |
| Source ID: | NCT03829891
|
| Associated Drug: |
Beinaglutide
|
| Title: |
Study for Beinaglutide Versus Glargine Therapy in Glycemic Variability of Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Beinaglutide|DRUG: glargine
|
| Outcome Measures: |
Primary: The proportion and rate of the fasting blood glucose control., Baseline and week 16|Proportion of patients with glycosylated hemoglobin < 7%., Baseline and week 16|Changes of blood sugar variation ., Baseline and week 16 | Secondary: Change percentage of glycosylated hemoglobin, Baseline and week16|Change of blood glucose, Baseline and week16|Change of blood pressure, Baseline and week16|Change of blood lipids, Baseline and week16|Change of body weight report in kilograms, Baseline and week16|Change of body mass index report in kg/m^2, Baseline and week16|Waist-hip ration change, Baseline and week16|Oxidative Stress Indice (8-Iso-PGF2α) change, Baseline and week16|Inflammatory factors (MCP-1) change, Baseline and week16|Inflammatory factors (hs-CRP) change, Baseline and week16 | Other: Safety Outcome Measure: Adverse Event, Adverse Event, From baseline to week 16|Safety Outcome Measure: Serious adverse event, Serious adverse event, From baseline to week 16
|
| Sponsor/Collaborators: |
Sponsor: Xijing Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2018-08-07
|
| Completion Date: |
2020-12-04
|
| Results First Posted: |
|
| Last Update Posted: |
2022-01-19
|
| Locations: |
Chang'an Hospital, Xi'an, China,Shanxi, 710016, China|Shaanxi Aerospace Hospital, Xi'an, China,Shanxi, 710025, China
|
| URL: |
https://clinicaltrials.gov/show/NCT03829891
|
